<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="DrugBank ID: db00135 DrugCentral: tyrosine Synonymous :(−)-α-amino-p-hydroxyhydrocinnamic acid | (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid | (s)-(-)-tyrosine | (s)-2-amino-3-(p-hydroxyphenyl)propionic acid | (s)-3-(p-hydroxyphenyl)alanine | (s)-alpha-amino-4-hydroxybenzenepropanoic acid | (s)-tyrosine | (s)-α-amino-4-hydroxybenzenepropanoic acid | 4-hydroxy-l-phenylalanine | l-tyrosin | l-tyrosine | tirosina | tyr | tyrosine | tyrosinum | y">

  
  <link rel="alternate" hreflang="en-us" href="https://bio-hub.github.io/drugpanel/tyrosine/info/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=UA-166873339-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'UA-166873339-1', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="https://bio-hub.github.io/drugpanel/tyrosine/info/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="PlatCOVID">
  <meta property="og:url" content="https://bio-hub.github.io/drugpanel/tyrosine/info/">
  <meta property="og:title" content="TYROSINE | PlatCOVID">
  <meta property="og:description" content="DrugBank ID: db00135 DrugCentral: tyrosine Synonymous :(−)-α-amino-p-hydroxyhydrocinnamic acid | (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid | (s)-(-)-tyrosine | (s)-2-amino-3-(p-hydroxyphenyl)propionic acid | (s)-3-(p-hydroxyphenyl)alanine | (s)-alpha-amino-4-hydroxybenzenepropanoic acid | (s)-tyrosine | (s)-α-amino-4-hydroxybenzenepropanoic acid | 4-hydroxy-l-phenylalanine | l-tyrosin | l-tyrosine | tirosina | tyr | tyrosine | tyrosinum | y"><meta property="og:image" content="https://bio-hub.github.io/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="https://bio-hub.github.io/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2019-05-05T00:00:00&#43;01:00">
    
    <meta property="article:modified_time" content="2019-05-05T00:00:00&#43;01:00">
  

  



  


  


  





  <title>TYROSINE | PlatCOVID</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link  active" href="/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  <article class="article">

  












  

  
  
  
<div class="article-container pt-3">
  <p style="font-size:25px" align="justify">TYROSINE</p>

  

  
    


<div class="article-metadata">

  
  

  

  

  

  
  
  

  
  

</div>

    














  
</div>



  <div class="article-container">

    <div class="article-style">
      
<script src="/rmarkdown-libs/kePrint/kePrint.js"></script>
<link href="/rmarkdown-libs/lightable/lightable.css" rel="stylesheet" />


<hr />
<p align="left" style="font-size:16px">
DrugBank ID: <a href='https://www.drugbank.ca/drugs/db00135' target='_blank'>db00135</a> <br>
DrugCentral: <a href="http://drugcentral.org/?q=tyrosine" target="_blank">tyrosine</a> <br>
Synonymous :(−)-α-amino-p-hydroxyhydrocinnamic acid | (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid | (s)-(-)-tyrosine | (s)-2-amino-3-(p-hydroxyphenyl)propionic acid | (s)-3-(p-hydroxyphenyl)alanine | (s)-alpha-amino-4-hydroxybenzenepropanoic acid | (s)-tyrosine | (s)-α-amino-4-hydroxybenzenepropanoic acid | 4-hydroxy-l-phenylalanine | l-tyrosin | l-tyrosine | tirosina | tyr | tyrosine | tyrosinum | y
</p>
<p><br></p>
<hr />
<div id="drug-sentece-context" class="section level2">
<h2>Drug Sentece Context</h2>
<br>
<p style="font-size:12px" align="center">
<strong>Table 1.</strong> Analysis of context sentence of <em>tyrosine</em> gene in 53 abstracts.
</p>
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
pmid
</th>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
sentence
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32345646" target="_blank">32345646</a>
</td>
<td style="text-align:center;">
As the SARS-CoV-2 (COVID19) pandemic spreads and the number of Bruton’s tyrosine kinase inhibitor (BTKi)-treated COVID19 affected patients grows, we must consider the pros and cons of BTKi discontinuation for our patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32387301" target="_blank">32387301</a>
</td>
<td style="text-align:center;">
The most promising drugs might be: Ruxolitinib, a JAK1/2 inhibitor, with a rapid and powerful anti-cytokine effect, tyrosine kinase inhibitors (TKIs), with their good anti-inflammatory properties, and perhaps the anti-Cd26 antibody Begelomab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32392389" target="_blank">32392389</a>
</td>
<td style="text-align:center;">
We studied the clinical course of COVID-19 in five hospitalized patients with autoimmune MG (four with acetylcholine receptor antibodies, one with muscle-specific tyrosine kinase antibodies) between April 1, 2020-April 30-2020.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32392559" target="_blank">32392559</a>
</td>
<td style="text-align:center;">
The biology of each leukemia and its corresponding treatment with conventional intensive chemotherapy, with or without targeted therapies (venetoclax, FLT3 inhibitors, IDH1/2 inhibitors, Bruton’s tyrosine kinase inhibitors), introduce additional layers of complexity during COVID-19 high-risk periods.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32395702" target="_blank">32395702</a>
</td>
<td style="text-align:center;">
Many viruses not only use growth factor receptors to physically attach to the cell surface and internalize, but also divert receptor tyrosine kinase signaling in order to replicate.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32424293" target="_blank">32424293</a>
</td>
<td style="text-align:center;">
There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32479682" target="_blank">32479682</a>
</td>
<td style="text-align:center;">
Uterine artery pulsatility index (UtAPI) and angiogenic factors (soluble fms-like tyrosine kinase-1/placental growth factor [sFlt-1/PlGF]) were assessed in women with suspected PE.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32489026" target="_blank">32489026</a>
</td>
<td style="text-align:center;">
GO annotation analysis suggested that Qingwen Baidu Yin Decoction may exert therapeutic effects by regulating protein phosphorylation, cell response to cytokine stimulation, cell proliferation, inflammatory response, transmembrane receptor protein tyrosine kinase signaling pathway, and cytokine-mediated signaling pathways.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32503877" target="_blank">32503877</a>
</td>
<td style="text-align:center;">
Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32583086" target="_blank">32583086</a>
</td>
<td style="text-align:center;">
This review addresses some of the pathways leading to endothelial derangement, such as complement, HIF-1α, and ABL tyrosine kinases.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32584418" target="_blank">32584418</a>
</td>
<td style="text-align:center;">
His white blood count (WBC) was 187×10<sup>9</sup> /L and bone marrow (Figure 1A &amp; 1C) examination revealed normal karyotype AML with a fms related receptor tyrosine kinase 3 (FLT3) internal tandem duplication (ITD), wild-type NPM1 and no additional mutations on a next-generation sequencing panel.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32640487" target="_blank">32640487</a>
</td>
<td style="text-align:center;">
Bruton’s tyrosine kinase (BTK) signaling is involved in innate immune responses and regulates the production of proinflammatory cytokines that can contribute to COVID-19 immunopathology.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32668701" target="_blank">32668701</a>
</td>
<td style="text-align:center;">
Among the top binding compounds we identified several tyrosine kinase inhibitors, which include a bioflavonoid, the group of natural products that binds best to 3CLpro.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32669298" target="_blank">32669298</a>
</td>
<td style="text-align:center;">
During the pandemic, ICI-containing regimens are chosen less often in favour of a tyrosine kinase inhibitors (TKI) monotherapy, mainly sunitinib or pazopanib (35%).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32672790" target="_blank">32672790</a>
</td>
<td style="text-align:center;">
Excess soluble fms-like tyrosine kinase 1 (sFlt-1), a soluble inhibitor of the vascular endothelial growth factor pathway, has been demonstrated to promote endothelial dysfunction.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32681385" target="_blank">32681385</a>
</td>
<td style="text-align:center;">
Axitinib (AXI) is a tyrosine kinase inhibitor, currently under investigation in an international phase II/III trial including thymic neuroendocrine tumors.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32688395" target="_blank">32688395</a>
</td>
<td style="text-align:center;">
Ninety patients (45%) were receiving active CLL therapy at COVID-19 diagnosis, most commonly Bruton tyrosine kinase inhibitors (BTKi’s; n = 68/90 [76%]).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32755479" target="_blank">32755479</a>
</td>
<td style="text-align:center;">
Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32788159" target="_blank">32788159</a>
</td>
<td style="text-align:center;">
Pre-eclampsia was subsequently ruled out by a low ratio of serum soluble fms-like tyrosine kinase-1 to placental growth factor.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32789663" target="_blank">32789663</a>
</td>
<td style="text-align:center;">
Ruxolitinib, a tyrosine kinase inhibitor selective for JAK1, 2, blocks many pro- and anti-inflammatory cytokines including IL6.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32814759" target="_blank">32814759</a>
</td>
<td style="text-align:center;">
Here, we performed a bioinformatic analysis of published and purported SARS-CoV-2 antivirals including imatinib mesylate that we found to suppress SARS-CoV-2 replication on Vero E6 cells and that, according to the published literature on other coronaviruses is likely to act on-target, as a tyrosine kinase inhibitor.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32829915" target="_blank">32829915</a>
</td>
<td style="text-align:center;">
A77 1726 inhibits the activity of protein tyrosine kinases (PTKs), p70 S6 kinase (S6K1), and dihydroorotate dehydrogenase (DHO-DHase).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32854573" target="_blank">32854573</a>
</td>
<td style="text-align:center;">
In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32879473" target="_blank">32879473</a>
</td>
<td style="text-align:center;">
However, as noted, no serum autoantibodies were observed against islet cells, glutamic acid decarboxylase, tyrosine phosphatase, insulin and zinc-transporter 8.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32955901" target="_blank">32955901</a>
</td>
<td style="text-align:center;">
Phenylalanine, tyrosine, glycine, lysine, and aspartic acid were found to be the headliner amino acids in the interactions between Arbidol and binding domains of spike glycoproteins in the SARS-CoV2 (Tab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32998369" target="_blank">32998369</a>
</td>
<td style="text-align:center;">
The vitamin K-dependent factors protein S (PROS1) and growth-arrest-specific gene 6 (GAS6) and their tyrosine kinase receptors TYRO3, AXL, and MERTK, the TAM subfamily of receptor tyrosine kinases (RTK), are key regulators of inflammation and vascular response to damage.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33014780" target="_blank">33014780</a>
</td>
<td style="text-align:center;">
Among compounds proposed to fight the SARS-CoV-2-related disease (COVID-19), tyrosine kinase inhibitors (TKIs), already effective in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML), have been proposed on the basis of their antiviral action already demonstrated against SARS-CoV-1.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33038418" target="_blank">33038418</a>
</td>
<td style="text-align:center;">
From the mechanistic point of view, interleukin-6, interleukin-1β receptor, interferon-gamma, tumor necrosis factor-alpha receptor, toll-like receptor, receptor tyrosine kinases, growth factor receptor, Janus kinase/signal transducers and transcription pathway, mammalian target of rapamycin, cytokine storm and macrophage activation have shown to play critical roles in COVID-19 complications.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33043320" target="_blank">33043320</a>
</td>
<td style="text-align:center;">
Ibrutinib, a known Burton’s tyrosine kinase (BTK) and interleukin-2 inducible T-cell kinase (ITK) inhibitor, is used for the treatment of B-cell disorders (chronic lymphocytic leukemia [CLL] and various other lymphomas) and chronic graft versus host disease following allogeneic hematopoietic cell transplantation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33101829" target="_blank">33101829</a>
</td>
<td style="text-align:center;">
Furthermore, we identified a specific substitution of tyrosine to histidine at position 41 in ACE2 that likely reduces the affinity to SARS-CoV-2 in horses and greater horseshoe bats.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33137863" target="_blank">33137863</a>
</td>
<td style="text-align:center;">
Other potential drugs that may be effective for COVID-19, are worthy of attention, including IL-6 monoclonal antibody, tyrosine protein kinase 1/2 inhibitor, cell therapy drugs, etc.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33170382" target="_blank">33170382</a>
</td>
<td style="text-align:center;">
The feeding of L-tyrosine shortened the time required to reach the stilbene productive stage.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33193390" target="_blank">33193390</a>
</td>
<td style="text-align:center;">
Specifically, the SOCS bind to the activation loop of receptor-associated tyrosine kinases JAK2 and TYK2 through the SOCS kinase inhibitory region (KIR), which inhibits STAT transcription factor activation by the kinases. […] The antagonist, pJAK2(1001-1013), is comprised of the JAK2 activation loop, phosphorylated at tyrosine 1007 with a palmitate for cell penetration.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33207699" target="_blank">33207699</a>
</td>
<td style="text-align:center;">
An untargeted analysis of non-critical COVID-19 patients identified a strong alteration of lipids and a perturbation of phenylalanine, tyrosine and tryptophan biosynthesis, phenylalanine metabolism, aminoacyl-tRNA degradation, arachidonic acid metabolism, and the tricarboxylic acid (TCA) cycle.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33226337" target="_blank">33226337</a>
</td>
<td style="text-align:center;">
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33245005" target="_blank">33245005</a>
</td>
<td style="text-align:center;">
The JAK/STAT signaling also mediates immune responses via B cell and T cell differentiation.With an attempt to reduce excessive inflammation, JAK/STAT inhibitors like Ruxolitinib, Baricitinib, Tofacitinib have been employed that mediate its actions via suppressors of cytokine signaling, cytokine inducible SH2 containing protein, Protein inhibitor of activated STAT and protein tyrosine phosphatases.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33254579" target="_blank">33254579</a>
</td>
<td style="text-align:center;">
Micronutrients, antiplatelets, ACE2 inhibitors, NSAIDs, corticosteroids and tyrosine kinase inhibitors are among the compounds discovered.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33259596" target="_blank">33259596</a>
</td>
<td style="text-align:center;">
Vaccinations are effective in preventing infections; however, it is unknown if patients with chronic lymphocytic leukemia (CLL) who are treatment naïve (TN) or receiving Bruton tyrosine kinase inhibitors (BTKi’s) respond to novel adjuvanted vaccines.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33328281" target="_blank">33328281</a>
</td>
<td style="text-align:center;">
Recently, Bruton tyrosine kinase (BTK) has emerged as an interesting candidate.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33396592" target="_blank">33396592</a>
</td>
<td style="text-align:center;">
Nintedanib is a synthetic orally active tyrosine kinase inhibitor, whose main action is to inhibit the receptors of the platelet-derived growth factor, fibroblast growth factor and vascular endothelial growth factor families.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33406218" target="_blank">33406218</a>
</td>
<td style="text-align:center;">
Moreover, the Bruton Tyrosine Kinase-inhibitor acalabrutunib and serotonin-dopamine receptor inhibitor drugs on our list have been found in the literature that have shown to be effective against Sars-CoV-2, while the path of activity is yet to be identified.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33420426" target="_blank">33420426</a>
</td>
<td style="text-align:center;">
In this study, we found that the tyrosine-protein kinase receptor UFO (AXL) specifically interacts with the N-terminal domain of SARS-CoV-2 S.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33421278" target="_blank">33421278</a>
</td>
<td style="text-align:center;">
The search for serum antibodies against the acetylcholine receptor, the muscle-specific tyrosine kinase (MuSK), and the low-density lipoprotein receptor-related protein 4 antibodies, performed by radioimmunoassay (RIA), resulted negative, while anti-MuSK antibodies were detected by cell-based assay (CBA).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33441177" target="_blank">33441177</a>
</td>
<td style="text-align:center;">
Bruton’s tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33477901" target="_blank">33477901</a>
</td>
<td style="text-align:center;">
Diarylureas are tyrosine kinase inhibitors well known in the art as anticancer agents, which might be useful tools for a reposition as antimicrobials.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33506114" target="_blank">33506114</a>
</td>
<td style="text-align:center;">
The first variant represented by 5% of samples that showed tyrosine deletion at Y144 located in the N terminal domain. […] The third variant, represented by 5%, showed aspartate substitution to tyrosine at D1139Y, and the fourth variant, represented by 5% glycine substitution to serine at G1167S.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33517358" target="_blank">33517358</a>
</td>
<td style="text-align:center;">
Drugs specifically developed for cancer therapy, such as interferons (IFN), the tyrosine KI abivertinib TKI (tyrosine kinase inhibitor) and interleukin-6 (IL-6) receptor inhibitors, may help control symptoms of Covid-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33539638" target="_blank">33539638</a>
</td>
<td style="text-align:center;">
HLA-C<em>15:227 differs from HLA-C</em>15:02:01:01 by a single nonsynonymous change (368A → G Tyrosine 99 to Cysteine).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33540371" target="_blank">33540371</a>
</td>
<td style="text-align:center;">
Signature analyses of B-cell receptors (BCRs) and T-cell receptors (TCRs) revealed the dominant selection of longer V-J pairs (e.g., IGHV3-9-IGHJ6 and IGHV3-23-IGHJ6) and continuous tyrosine motifs in BCRs and lower diversity of TCRs.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33560402" target="_blank">33560402</a>
</td>
<td style="text-align:center;">
Tyrosine kinase inhibitors (TKIs) are used to target dysregulated signaling pathways in virtually all hematologic malignancies. […] Based on in vitro and clinical observations, we attempt to decipher the impact of the main TKIs approved or in late-stage development for the treatment of hematological malignancies, including inhibitors of Bruton’s tyrosine kinase, spleen tyrosine kinase, BCR-Abl, phosphatidylinositol 3-kinase/ mammalian target of rapamycin, JAK/STAT, and FMS-like tyrosine kinase 3, to provide a rationale for how such inhibitors could modify clinical courses of diseases, such as COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33571819" target="_blank">33571819</a>
</td>
<td style="text-align:center;">
Also, protein tyrosine kinase inhibition is an additional mechanistic benefit of LF, which inhibits immunological events such as cellular expansion and immunoglobulin production with an enhanced release of immunosuppressant cytokines.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33585346" target="_blank">33585346</a>
</td>
<td style="text-align:center;">
The rates of intensive care unit admission and mechanical ventilation support, and lengths of hospital stay were lower in COVID-19 patients with CML receiving tyrosine kinase inhibitors (TKI) compared with an age, gender and comorbidity-matched control group.Our case report and review of the literature suggest a possible protective effect of TKI therapy against COVID-19 in patients with CML.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33589624" target="_blank">33589624</a>
</td>
<td style="text-align:center;">
Our analysis highlights the importance of serine/threonine and tyrosine kinases as potential targets that intersect the SARS-CoV-2 and aging pathways.
</td>
</tr>
</tbody>
</table>
</div>

    </div>

    





















  </div>
</article>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/academic.min.4aaf2d64e50f8e54cf66dcc54147a22e.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      
      <a href="/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
